Illumina launches StrataMap Spatial Solution

Illumina, a global leader in DNA sequencing, announced the launch of its StrataMap Spatial Solution on June 8, 2026. This end-to-end sequencing-based research solution offers unmatched breadth of coverage and resolution for spatial transcriptomics, enabling researchers to map tissue structure, reveal tissue function, track tumor progression, and identify novel drug targets. The solution provides single-cell resolution, unbiased whole-transcriptome profiling, and a large capture area, detecting twice as many genes as alternative technologies. Early pilot programs at Beth Israel Deaconess Medical Center and Institute of Cancer Research, in collaboration with University of Cambridge, have demonstrated its high sensitivity and utility in mapping complex tissues and characterizing tumor microenvironments. The StrataMap Spatial Solution is designed for scalability and accessibility, integrating into existing histopathology workflows and running on Illumina's NovaSeq and NextSeq platforms. It also includes a comprehensive bioinformatics pipeline for data processing and analysis.